Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Conditions
- NSCLC Patients With Brain Metastasis
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT06970639
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangdong, Guangzhou, China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 21
- Registration Number
- NCT06969612
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
- Conditions
- Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexateVinblastineDoxorubicinCisplatinGemcitabine
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06960577
- Locations
- 🇪🇸
Research Site, Santiago de Compostela, Spain
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- VSPharmTech Co.,Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06959082
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06956001
- Locations
- 🇨🇳
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, BeiJing, Beijing, China
🇨🇳Shandong Tumor Hospital, Shandong, Jinan, China
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT06946797
- Locations
- 🇵🇱
Local Institution - 0079, Łódź, Łódzkie, Poland
🇧🇷Local Institution - 0041, Brasilia, Distrito Federal, Brazil
🇺🇸Local Institution - 0032, Anchorage, Alaska, United States
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Conditions
- CNS Embryonal TumorCNS, MedulloblastomaAtypical Teratoid Rhabdoid TumorMedulloblastoma, ChildhoodMedulloblastoma, Group 3Medulloblastoma, Group 4PineoblastomaEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 15
- Registration Number
- NCT06942039
Toripalimab With Chemotherapy for Sinus Cancer
- Conditions
- Sinonasal CancerParanasal Sinus NeoplasmsSquamous Cell CarcinomaSinonasal Undifferentiated CarcinomaLocally Advanced Head and Neck Cancer
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 20
- Registration Number
- NCT06940180
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.
- Conditions
- EGFR-mutated Locally Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT06927986
Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06927128
- Locations
- 🇨🇳
Changhai hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.